Trey Martin

Trey Martin has more than 25 years of executive leadership experience in life sciences operations, engineering, sales, and marketing. Prior to joining Maravai, he was most recently Senior Vice President, of Genomic Medicines, part of Danaher Corporation, where he oversaw new business creation in the areas of mRNA, gene editing, and gene therapy. Mr. Martin originally joined Danaher with the acquisition of Integrated DNA Technologies (IDT) in 2018, serving as President of IDT. Prior to the acquisition by Danaher, Mr. Martin held positions of increasing responsibility over his more than two decades of tenure at IDT and contributed to the consistent growth and competitiveness of the company’s primary oligo synthesis business through directing organic and inorganic growth investments, including product portfolio and service capability expansions, strategic customer collaborations and global M&A in the nucleic acid space. Mr. Martin holds a bachelor’s degree in biochemistry from the University of Iowa.